The latest price target for PAVmed (NASDAQ:PAVM) was reported by Cantor Fitzgerald on August 18, 2023. The analyst firm set a price target for $1.40 expecting PAVM to rise to within 12 months (a possible 88.32% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for PAVmed (NASDAQ:PAVM) was provided by Cantor Fitzgerald, and PAVmed reiterated their neutral rating.

There is no last upgrade for PAVmed

The last downgrade for PAVmed Inc happened on January 20, 2023 when Cantor Fitzgerald changed their price target from $4 to $1.5 for PAVmed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PAVmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PAVmed was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.

While ratings are subjective and will change, the latest PAVmed (PAVM) rating was a reiterated with a price target of $0.00 to $1.40. The current price PAVmed (PAVM) is trading at is $0.74, which is within the analyst’s predicted range.